| abstract |
There is increasing evidence for crosstalk between S1P1R and other growth factor receptors such as PDGFR. Thus, S1P1 receptor antagonists may provide clinical utility as anticancer treatments. The present disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising S1P receptor antagonists, and methods of using and manufacturing S1P receptor antagonists. In particular, the present disclosure provides sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising S1P1 receptor antagonists, and methods of using S1P1 receptor antagonists for cancer treatment and the like and S1P1 receptor The present invention relates to a method for producing a body antagonist. |